StackItSmart

Compound reference

Tesamorelin

Egrifta

Peptides3 cited findingsClinical review: not reviewed

Regulatory record

Regulatory recordSupporting passage inspected

Egrifta WR is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management, and long-term cardiovascular safety has not been established.[1]

Jurisdiction
United States
Product
EGRIFTA WR (tesamorelin)
Indication
Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy
Record date
2026-09-08
  • The indication is specific to the approved product and HIV-associated lipodystrophy.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

· Independent fresh reinspection for the deep-evidence pass: reopened every cited source at its passages via NCBI E-utilities / DailyMed / accessdata.fda.gov / govinfo.gov / Wayback Machine mirror, checked Europe PMC correction/retraction metadata where applicable, and confirmed the claim's wording against the primary text. Disposition: supported within the stated scope. No qualified clinical review.

Safety findings

Regulatory recordSupporting passage inspected

Egrifta WR is contraindicated in pregnancy, active malignancy and disruption of the hypothalamic-pituitary axis, among other labeled conditions. The label also addresses elevated IGF-1, glucose intolerance and fluid retention.[1]

  • A selected safety summary; consult the full label for all contraindications and monitoring information.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

· Independent fresh reinspection for the deep-evidence pass: reopened every cited source at its passages via NCBI E-utilities / DailyMed / accessdata.fda.gov / govinfo.gov / Wayback Machine mirror, checked Europe PMC correction/retraction metadata where applicable, and confirmed the claim's wording against the primary text. Disposition: supported within the stated scope. No qualified clinical review.

Pharmacokinetics

Regulatory recordSupporting passage inspected

Egrifta WR and Egrifta SV are not substitutable. For WR, the label reports an approximately 11-minute elimination half-life after a single subcutaneous dose in healthy participants; a different formulation’s estimate should not be displayed as universal.[1]

  • This half-life is tied to the WR formulation and the labeled pharmacokinetic study.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

· Independent fresh reinspection for the deep-evidence pass: reopened every cited source at its passages via NCBI E-utilities / DailyMed / accessdata.fda.gov / govinfo.gov / Wayback Machine mirror, checked Europe PMC correction/retraction metadata where applicable, and confirmed the claim's wording against the primary text. Disposition: supported within the stated scope. No qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Restricted the regulatory, pharmacokinetic and selected safety findings to the inspected Egrifta WR label and formulation.

  • Other formulations and broad obesity or performance applications need separate evidence.
  • Other inherited assertions not supported by the published claim set remain unverified; no qualified clinician review has occurred.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. EGRIFTA WR (tesamorelin) US prescribing information

    Theratechnologies Inc., US Food and Drug Administration. DailyMed SPL Set ID 839334d3-8c1d-4c26-9036-2ab524a6ea75, Version 2, Effective Time 2026-07-29; labeled text revision March 2025. 2025-03. Product label.

    Inspected location: Highlights and full Sections 1, 2.1, 4, 5.1, 12.3; patient labeling revision stamp; DailyMed SPL packaging metadata

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • peptide-egrifta-wr-2025: Sections 1, 2.1, 4, 5 and 12.3

View this compound in the research library →

Related records in this class

Grouped under Peptides for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.